Navigation Links
Major New Review Supports the Broader Potential of CeNeS COMT,Inhibitor Discovery Programme

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN) ("CeNeS" or "the Company") the Cambridge-based biopharmaceutical company today announced that a paper published this week in CNS Drugs(1) further supports the hypothesis that a catechol-O-methyltransferase (COMT) inhibitor that acts in the brain would be a useful agent to address profound cognitive deficits in schizophrenia and bipolar disorder. CeNeS has an ongoing discovery programme to develop novel COMT inhibitors.

The paper reviews the preclinical and clinical data surrounding COMT and includes studies carried out by the world leading group based at the National Institute of Mental Health, Bethesda, Maryland, USA. The paper's authors collate recent developments in the analysis of the role of COMT genotypes and their involvement in cognitive deficits in schizophrenia and bipolar disorder. The paper supports the view that there is potential to use COMT inhibitors in ameliorating their cognitive deficits via an effect on prefrontal cortex brain function. As part of their conclusions the authors note, "The development of newer COMT inhibitors that can permeate the BBB (blood brain barrier) effectively and are devoid of serious adverse effects will allow expansion of the search for more specific, selective therapies for the treatment of cognitive disorders".

CeNeS has a leading position in the discovery of a novel series of COMT inhibitors with a programme currently focused on drugs for treatment of Parkinson's disease. In addition to this, the continuing progression of the scientific rationale for the potential use of COMT inhibitors in the treatment of schizophrenia and bipolar disorder places the CeNeS discovery programme in a good position in an exciting area of neuroscience.

Neil Clark, Chief Executive of CeNeS said: "CeNeS is excited about its discovery programme's potential to deliver improved drugs for the treatment of
'"/>




Page: 1 2 3 4

Related medicine technology :

1. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
2. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
3. Pooled Studies Showed Desvenlafaxine Succinate Significantly Improved Painful Symptoms and Anxious Symptoms Associated with Major Depressive Disorder in Adults, Compared With Placebo
4. Six-Week Investigational Study In Adults With Major Depressive Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole Therapy With Antidepressants
5. Major Manufacturer of Unapproved and Adulterated Drugs
6. Exforge Helps Vast Majority of Patients Effectively Control Their Blood Pressure After Failing on Other Medicines, According to New Clinical Data
7. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
8. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
9. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
10. New Clinical Data for Cytogens Quadramet and Prostacint to be Reported at Upcoming Major Medical Meetings
11. Major Discovery Raises Prospect of Better Patient Care By Improving Platelet Life Span
Post Your Comments:
(Date:10/13/2008)...ave Higher Sensitivity and Specificity, than Othe...he preferred test in all phases of...- AT First Diagnostic LLC an,emerging...st kits, today,announced that a recent evaluation ...earch of the FirstVue(TM) HBSAG Test, was released...
(Date:10/13/2008)...tiple Cancer Populations Facilitates ...Oct. 13 /- Rubicon Genomics, Inc. tod...mplify DNA samples for The,Cancer Atlas Genome Pro...nd standardize total genomic,DNA from 3,000 tissue...on,GenomePlex(TM) Whole Genome Amplification techn...
(Date:10/12/2008)...in Combination with Chemotherapy, FREMONT, Calif....c., a,development-stage pharmaceutical company dis...Ai)-based therapeutics, today announced that the,j...cy of siRNA targeting,its proprietary target gene ...edition dated October 1, 2008. The paper, entitled...
(Date:10/12/2008)...t. 12 /- Boston,Scientific ...from an analysis,of nearly 7,500 patients from its...ed to confirm the performance of the TAXUS(R) Expr...in real-world practice. The,two-year pooled ARRIVE...,restenosis in patients with diabetes as effective...
Breaking Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 2Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 2Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 3Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 1Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 2Patti LaBelle Wows Crowd at 5th Annual Lupus Foundation of America Awards Gala 18813 3Previously unseen switch regulates breast cancer response to estrogen 18812 1Previously unseen switch regulates breast cancer response to estrogen 18812 2Phase III pivotal results presented of VYVANSE to treat ADHD in adults 18811 1Phase III pivotal results presented of VYVANSE to treat ADHD in adults 18811 2Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life Including Pregnancy 18807 1Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life Including Pregnancy 18807 2Omron Makes Blood Pressure Monitoring Easy for Women at Any Stage of Life Including Pregnancy 18807 3
...ically meaningful pain relief within 5,minutes of ... June 2007 - Archimedes Pharma Ltd,("Archimedes"),...y,presented new clinical data from a Phase II stud...nasal spray aimed at providing a,fast, effective a...in. Data were presented at the 10th Congress of th...
...ating zonisamide SR as a novel component in,EMPATI... 2007 /PRNewswire-FirstCall/ -- Orexigen(TM),Thera...d on the,treatment of central nervous system disor...nced results from a Phase I trial evaluating,safet...sustained-release (SR) formulation of zonisamide. ...
Other Medicine Technology:Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 2Archimedes Pharma Presents Positive Efficacy and Safety Data on,Nasalfent at European Association for Palliative Care Congress 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
... of Indian MPs has come together to launch a fight...have planned to start a massive awareness drive an...i-TB drug. It is stated that at least two people d...ee minutes. Around 20 MPs have decided to form ...
...sts linked with Harvard Medical School claim the d... breast tumors from malignant ones.// Harvard’s K...p that participated in the research, described det...33rd national meeting of the American Chemical soc...
...ng to a series of papers published in The Lancet o...nagers is less healthy when compared to their pare...lio and tuberculosis have given way to venereal di...drug abuse etc. The only silver lining to this iss...
...d families of persons infected with deadly viruses...w get a chance to understand how. // An independe...ting of these deadly infections by almost 2000 hem..., in what is acknowledged as the biggest treatment...
Other Medicine News:Health News:Indian Parliamentarians Join to Fight Against TB 2Health News:Detection of Malignant Breast Tumors Made Simpler and More Effective 2Health News:Inquiry into Past NHS Treatment Disaster 2
Gentamicin Reagent Solution (10 mg/ml) liquid
LB Agar plates with 0.1mM EDTA.
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride.
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride.
Medicine Products: